There were 381 press releases posted in the last 24 hours and 427,892 in the last 365 days.

Contact

Please use this form to send email to PR contact of this press release:
Biofrontera AG: Pivotal Phase III Data Demonstrate Significant Efficacy and Excellent Safety for BF-200 ALA Treatment of Superficial Skin Cancer

TO:



FROM:

Please check your email address!

Please, do not fill this field.

Please, do not change this field.

Please, do not fill if your javascript is turned off.

captcha image